Vidaza recommended in Japan for MDS
This article was originally published in Scrip
Executive Summary
Nippon Shinyaku's Vidaza (azacitidine; NS-17) has received a positive approval opinion in Japan for the treatment of myelodysplastic syndromes (MDS).